ArticleJournal of cellular and molecular medicine2025
CD39 Contributes to the Ability of Cell Invasion in Heterogeneity of Colorectal Cancer.
Article in Journal of cellular and molecular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The promoting roles of GLP1R and GIPR in stemness maintenance and multiple lineage-specific differentiation of PDLSCs.Cellular & molecular biology letters · 2026Article
- CD39 and CD73: biological functions, diseases and therapy.Molecular biomedicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Tumour heterogeneity will accumulate and amplify during cell culture and passage, even if derived from the same strain. In the current study, multiple batches of colorectal cancer HCT116 and HT29 cell lines were obtained using different conditions of trypsin digestion and processed for RNA sequencing. CD39 was identified as a biomarker highly expressed in easily trypsin-digested cells compared to the undigestible ones. Furthermore, CD39 was determined to enhance cell invasion and suppress cell apoptosis but not affect cell proliferation. Moreover, CD39 could activate the TGF-β/SMAD3 signalling pathway, whereas the expression of CD39 was negatively regulated by SMAD3 via recruitment of SETDB1 and adding H3K9me3 to the CD39 promoter in HCT116 cells. Overall, our study uncovered distinct gene signatures amongst different heterogeneities of colorectal cells and revealed the effect of CD39 on cell invasion and apoptosis, as well as determined the epigenetic role in regulating CD39 transcription.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.